查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1438227

至 2030 年花生过敏治疗市场预测：按治疗类型、给药途径、最终用户和地区进行的全球分析

Peanut Allergy Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type (Epinephrine, Antihistamines & Corticosteroids, Immunotherapy & Other Treatment Types), By Route Of Administration (Oral & Injectable), End User & By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球花生过敏治疗市场规模为 5.161 亿美元，预计到 2030 年将达到 11.698 亿美元，预测期内复合年增长率为 12.4%。

花生过敏治疗包括多种策略来控制和减轻因食用花生而引起的过敏反应。方法包括避免过敏原、肾上腺素紧急干预以及旨在使免疫系统脱敏的过敏原免疫疗法。这些治疗方法旨在提高患者的安全性，最大限度地减少过敏反应，并提高花生过敏患者的整体生活品质。

根据ITC的贸易地图，2021年阿根廷出口了634,080吨花生，其次是印度，出口量为563,268吨。

花生过敏盛行率增加

随着全世界被诊断出患有花生过敏的人数增加，对有效治疗方法的需求也增加。这一趋势正在推动创新治疗方法的研究和开发，包括过敏原免疫疗法、紧急干预措施和预防措施。此外，随着製药公司和医疗保健提供者满足对先进且易于使用的治疗方法的需求，以管理和降低与花生过敏相关的风险，不断扩大的患者群体正在推动市场成长。

昂贵的治疗费用

与过敏原免疫治疗、紧急干预和持续医疗管理相关的成本增加了患者和医疗保健系统的经济负担。由于某些治疗的保险范围有限，成本障碍进一步加剧。这种高昂的财务障碍可能会阻止患者寻求或继续治疗，影响患者的依从性和整体治疗结果。

提高知晓率和诊断率

提高医疗保健专业人员和公众对花生过敏的认识将有助于及早发现和诊断。随着意识的提高，更多的患者将寻求医疗救助，治疗选择也会增加。这种趋势不仅可以透过及时介入来改善患者的治疗效果，而且还推动了对有效花生过敏治疗的需求。上市公司和医疗保健提供者可以利用这一机会，开发创新治疗方法，促进教育倡议，并促进医学界和公众对花生过敏的更全面了解。

接触专家和治疗中心的机会受到限制

获得专家和治疗中心的机会有限是花生过敏治疗市场的主要威胁。花生过敏的患者在寻求专业医疗保健专业人员和指定治疗设施方面可能会遇到挑战。这种限制可能会阻碍及时诊断、个人化治疗计划和过敏原免疫疗法的实施。缺乏训练有素的专家可能会导致患者照护方面的差距并影响干预措施的有效性。

COVID-19 的影响

COVID-19 大流行造成了包括过敏诊断和治疗在内的医疗服务中断，影响了花生过敏治疗市场。医疗保健优先事项的关闭、限制和转变延迟了患者护理、诊断和治疗的开始。此外，疫情也影响了临床试验和研究活动，影响了花生过敏治疗的整体情况。随着局势稳定，市场逐渐復苏，人们更加重视病人安全和创新治疗方法。

免疫治疗领域预计将成为预测期内最大的市场

预计免疫疗法领域将在预测期内主导花生过敏治疗市场。这一优点是由于越来越多地采用过敏原免疫疗法，包括皮下和舌下方法，旨在使免疫系统对花生脱敏。免疫疗法专注于解决花生过敏的根本原因并减少过敏反应，已成为首选治疗选择，有助于该类别市场占有率的显着增长。

预计注射剂领域在预测期内的复合年增长率最高。

在预测期内，花生过敏治疗市场预计注射剂领域将出现良好成长。推动这一增长的是对注射治疗的日益偏好，特别是在严重过敏反应的紧急管理中使用肾上腺素自动注射器。随着人们越来越关注过敏紧急情况的快速有效干预，注射剂领域有望显着增长，为患者和看护者提供方便有效的解决方案。

比最大的地区

由于其先进的医疗基础设施、对花生过敏的认识不断提高以及积极的法规环境，北美预计将主导花生过敏治疗市场。该地区对免疫疗法等创新治疗方法的关注以及花生过敏的高盛行率也是其市场领先地位的因素。此外，医疗和研究机构之间的合作正在推动花生过敏治疗的进步，使北美成为开发和市场开拓的主要地点。

复合年增长率最高的地区

在欧洲地区，由于花生过敏盛行率不断上升、对医疗保健研究的重视以及治疗方案的进步，花生过敏治疗市场预计将快速成长。医疗保健专业人员和患者意识的提高，加上支持性的法律规范，正在推动创新花生过敏治疗方法的采用。随着研究和开发的加强，欧洲为花生过敏治疗的进步做出了重大贡献，推动了预测期内市场的显着成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间存在敌对关係

第五章全球花生过敏治疗市场：依治疗类型

  • 肾上腺素
  • 抗组织胺和皮质类固醇
  • 免疫疗法
  • 其他治疗类型

第六章全球花生过敏治疗市场：依给药途径

  • 口服
  • 可注射的

第七章全球花生过敏治疗市场：依最终用户分类

  • 医院
  • 诊所
  • 门诊手术中心
  • 家庭护理设置

第八章全球花生过敏治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Aimmune Therapeutics
  • ALK-Abello A/S
  • Alladapt Immunotherapeutics, Inc
  • AnaptysBio, Inc.
  • DBV Technologies SA
  • GlaxoSmithKline plc
  • HAL Allergy Group
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Prota Therapeutics
  • Regeneron Pharmaceuticals
  • Sanofi
  • Stallergenes Greer
Product Code: SMRC25196

According to Stratistics MRC, the Global Peanut Allergy Treatment Market is accounted for $516.1 million in 2023 and is expected to reach $1169.8 million by 2030 growing at a CAGR of 12.4% during the forecast period. Peanut allergy treatment involves various strategies to manage and alleviate allergic reactions triggered by the consumption of peanuts. Approaches include allergen avoidance, emergency interventions with epinephrine, and allergen immunotherapy, aimed at desensitizing the immune system. These treatments aim to enhance patient safety, minimize allergic responses, and improve the overall quality of life for individuals with peanut allergies.

According to the ITC trade map, in 2021, Argentina exported 634,080 metric ton of peanuts, followed by India with 563,268 metric ton in second place.

Market Dynamics:

Driver:

Increasing prevalence of peanut allergy

With a rising number of individuals diagnosed with peanut allergies globally, there is a growing need for effective treatment options. This trend propels research and development efforts towards innovative therapies, including allergen immunotherapy, emergency interventions, and preventive measures. Moreover, the expanding patient pool fosters market growth as pharmaceutical companies and healthcare providers address the demand for advanced and accessible treatments to manage and mitigate the risks associated with peanut allergies.

Restraint:

High cost of treatment

Expenses associated with allergen immunotherapy, emergency interventions, and ongoing medical management contribute to the financial burden on patients and healthcare systems. Limited insurance coverage for certain treatments further exacerbates the cost barrier. This high financial threshold may deter some individuals from seeking or continuing treatment, impacting overall patient adherence and outcomes.

Opportunity:

Rising awareness and diagnosis rates

Increased awareness among healthcare professionals and the general public about peanut allergies leads to early detection and diagnosis. As awareness grows, more individuals seek medical attention, creating a larger patient pool for treatment options. This trend not only improves patient outcomes by enabling timely interventions but also drives the demand for effective peanut allergy treatments. Pharmaceutical companies and healthcare providers can capitalize on this opportunity by developing innovative treatments, fostering education initiatives, and contributing to a more comprehensive understanding of peanut allergies in both medical communities and the public.

Threat:

Limited access to specialists and treatment centers

Limited access to specialists and treatment centers poses a significant threat to the peanut allergy treatment market. Patients facing peanut allergies may encounter challenges in accessing specialized healthcare professionals and designated treatment facilities. This limitation can hinder timely diagnosis, personalized treatment plans, and the administration of allergen immunotherapy. The scarcity of trained specialists may contribute to gaps in patient care, impacting the effectiveness of interventions.

Covid-19 Impact:

The COVID-19 pandemic has impacted the peanut allergy treatment market by causing disruptions in healthcare services, including allergy diagnostics and treatments. Lockdowns, restrictions, and shifts in healthcare priorities led to delays in patient care, diagnosis, and treatment initiation. Additionally, the pandemic affected clinical trials and research activities, influencing the overall landscape of peanut allergy treatment. As the situation stabilizes, the market is gradually recovering, with an increased emphasis on patient safety and innovative treatment approaches.

The Immunotherapies segment is expected to be the largest during the forecast period

The immunotherapies segment is anticipated to be the largest in the peanut allergy treatment market during the forecast period. This dominance is attributed to the increasing adoption of allergen immunotherapy, including subcutaneous and sublingual approaches, aimed at desensitizing the immune system to peanuts. With a focus on addressing the root cause of peanut allergies and reducing allergic reactions, immunotherapies emerge as a preferred treatment option, contributing to the segment's substantial market share growth.

The injectable segment is expected to have the highest CAGR during the forecast period

The injectable segment is projected to experience lucrative growth in the peanut allergy treatment market during the forecast period. This growth is driven by the increasing preference for injectable forms of treatment, particularly the use of epinephrine auto-injectors for emergency management of severe allergic reactions. With a heightened focus on rapid and efficient intervention during allergic emergencies, the injectable segment is poised for substantial growth, offering a convenient and effective solution for patients and caregivers.

Region with largest share:

North America is poised to dominate the peanut allergy treatment market due to advanced healthcare infrastructure, heightened awareness of peanut allergies, and a proactive regulatory environment. The region's focus on innovative therapies, including immunotherapies, and a higher prevalence of peanut allergies contribute to its market leadership. Additionally, collaborations between healthcare organizations and research institutions further drive advancements in peanut allergy treatment, positioning North America as a key hub for developments and market dominance.

Region with highest CAGR:

The European region foresees rapid growth in the peanut allergy treatment market due to the increasing prevalence of peanut allergies, a strong emphasis on healthcare research, and advancements in treatment options. Rising awareness among healthcare professionals and patients, coupled with supportive regulatory frameworks, propels the adoption of innovative peanut allergy therapies. As research and development efforts intensify, Europe emerges as a significant contributor to advancements in peanut allergy treatment, driving substantial market growth in the forecasted period.

Key players in the market

Some of the key players in Peanut Allergy Treatment Market include Aimmune Therapeutics, ALK-Abello A/S, Alladapt Immunotherapeutics, Inc, AnaptysBio, Inc., DBV Technologies SA, GlaxoSmithKline plc, HAL Allergy Group, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Prota Therapeutics, Regeneron Pharmaceuticals, Sanofi and Stallergenes Greer.

Key Developments:

In June 2023, Alladapt Immunotherapeutics, Inc. has unveiled topline results of Phase 1/2 Harmony study assessing effectiveness & safety of ADP101 for treating food allergies. Outcomes indicate dose-dependent, clinically significant responses, and a favorable safety profile in pediatric patients with single or multiple food allergies. These promising findings suggest ADP101's potential as a safe and effective treatment for children with common food allergies.

In May 2023, DBV Technologies has made an announcement that the results of its Phase 3 EPITOPE trial involving EPIT using Viaskin Peanut in children aged 1 to 3 years have been published in the New England Journal of Medicine. This publication underscores the potential of a new food allergy treatment option for this specific age group, offering hope for the management of food allergies in young children.

Treatment Types Covered:

  • Epinephrine
  • Antihistamines and Corticosteroids
  • Immunotherapy
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Injectable

End Users Covered:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Peanut Allergy Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Epinephrine
  • 5.3 Antihistamines and Corticosteroids
  • 5.4 Immunotherapy
  • 5.5 Other Treatment Types

6 Global Peanut Allergy Treatment Market, By Route Of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Injectable

7 Global Peanut Allergy Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.5 Ambulatory Surgical Centers
  • 7.6 Homecare Settings

8 Global Peanut Allergy Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Aimmune Therapeutics
  • 10.2 ALK-Abello A/S
  • 10.3 Alladapt Immunotherapeutics, Inc
  • 10.4 AnaptysBio, Inc.
  • 10.5 DBV Technologies SA
  • 10.6 GlaxoSmithKline plc
  • 10.7 HAL Allergy Group
  • 10.8 Merck & Co., Inc.
  • 10.9 Mylan N.V.
  • 10.10 Novartis AG
  • 10.11 Pfizer Inc.
  • 10.12 Prota Therapeutics
  • 10.13 Regeneron Pharmaceuticals
  • 10.14 Sanofi
  • 10.15 Stallergenes Greer

List of Tables

  • Table 1 Global Peanut Allergy Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 3 Global Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 4 Global Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 5 Global Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 6 Global Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 7 Global Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 8 Global Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 9 Global Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 10 Global Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 11 Global Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 12 Global Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 13 Global Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 14 Global Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 15 North America Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 17 North America Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 18 North America Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 19 North America Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 20 North America Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 21 North America Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 22 North America Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 23 North America Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 24 North America Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 North America Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 26 North America Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 27 North America Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 28 North America Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 29 Europe Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 31 Europe Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 32 Europe Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 33 Europe Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 34 Europe Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 35 Europe Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 36 Europe Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 37 Europe Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 38 Europe Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 39 Europe Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 40 Europe Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 41 Europe Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 42 Europe Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 43 Asia Pacific Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 45 Asia Pacific Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 46 Asia Pacific Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 47 Asia Pacific Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 48 Asia Pacific Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 49 Asia Pacific Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 50 Asia Pacific Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 51 Asia Pacific Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 52 Asia Pacific Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 53 Asia Pacific Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 54 Asia Pacific Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 55 Asia Pacific Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 56 Asia Pacific Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 57 South America Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 59 South America Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 60 South America Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 61 South America Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 62 South America Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 63 South America Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 64 South America Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 65 South America Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 66 South America Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 67 South America Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 68 South America Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 69 South America Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 70 South America Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 71 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 73 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 74 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 75 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 76 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 77 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 78 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 79 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 80 Middle East & Africa Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 81 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 82 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 83 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 84 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)